You are here: Industry Insights > Humira

News List

AbbVie's first-quarter sales top estimates, boosted by Humira, hepatitis C drugs firstwordpharma
April 27, 2018
AbbVie announced Thursday that first-quarter sales increased 21.4 percent year-over-year to $7.9 billion, topping analyst estimates of $7.6 billion
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab) biospace
April 12, 2018
Mylan N.V. today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to Humira® developed by Fujifilm Kyowa Kirin Biologics.
Biogen, Bioepis resolve dispute over Humira biosimilar biospectrumasia
April 08, 2018
AbbVie will grant patent licenses for the biosimilar, branded as IMRALDI, in Europe on a country-specific basis.
Top 50 Drugs by Global Sales in 2017: Humira Topped for 6 Times Dopine
March 06, 2018
Humira continued to be strong, with sales of 2017 fiscal year growing by USD 2.69 billion to reach USD 18.427 billion in total, becoming a “6-time champion”.
Boehringer celebrates EU approval of Humira biosimilar pharmafile
November 15, 2017
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, confirming that is comparable in safety and efficacy to its originator produc
Thanks to Amgen biosim settlement, AbbVie’s $20B Humira forecast looks real fiercepharma
September 29, 2017
AbbVie's assertion that Humira will sail clear for several years gained strength on Thursday as the drugmaker inked a patent settlement with Amgen, holding off that company's biosimilar until 2023.
Five more biosimilar-free years for AbbVie’s Humira pharmafile
September 29, 2017
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the $20 billion region per year region before competition arrives.
Summary of Development Process of Antibody Innovation, Antibody Engineering Entering the Golden Days en-cphi.cn
September 19, 2017
The development of antibody drugs has been 30 years, from 1984 when world’s first monoclonal antibody drug Orthoclone OKT3 was approved by FDA to the year when AbbVie’s Humira became world’s best-selling drug.
Biogen, Samsung Humira copy wins EU approval fiercepharma
August 28, 2017
A second biosimilar of AbbVie's Humira, the world's top-selling drug at $16 billion, has been approved in Europe.
A 10 years' Top 10 patent losses worth a tremendous $915B in lifetime sales fiercepharma
August 18, 2017
The top patent losses of the last 10 years have bring that situation to new—even record-setting—heights.

Previous page 1 2 3 4 5 6 7 Next page